Thank you for writing to us. One of our executive will reach back to you through your submitted medium. In case there’s an urgency, feel free to connect over WhatsApp for faster response.
Prefer calling? Dial +9108048034334 (International callers) or 08048034334 (Indian callers).
CITICOLIN 250 INJ (citicoline 250 mg injection) is a neuroprotective medicine used under the supervision of a healthcare professional for the treatment and management of various neurological conditions.
Stroke: Used in both the acute and recovery phases of ischemic stroke (caused by blood clots) to support brain function and help regain abilities like movement or speech that may have been affected.
Head Injury: Aids in the recovery from traumatic brain injuries by helping to restore consciousness and improve cognitive functions like focus and memory.
Alzheimer's Disease: Used to help slow cognitive decline and support memory, attention, and overall mental clarity in patients with Alzheimer's.
Dementia in Parkinson's Disease: Helps improve memory, alertness, and thinking ability in individuals experiencing dementia as a result of Parkinson's disease.
Disturbances of Consciousness: Administered to manage disturbances of consciousness resulting from brain operations or damage to brain tissues.
Dapagliflozin tablets (brand name options include Farxiga and Forxiga) are a prescription medication used to treat several serious conditions in adults, and type 2 diabetes in children and adolescents.
Key indications for dapagliflozin include its use as an addition to diet and exercise for improved blood sugar control in adults and children aged 10 and above with type 2 diabetes. It is also prescribed to adults with heart failure to lower the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits, regardless of their ejection fraction. Additionally, dapagliflozin is used in adults with chronic kidney disease who are at risk of progression, with or without type 2 diabetes, to reduce the risk of a sustained decline in kidney function (eGFR), end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.